Abbott CMO Dr. Nick West touts latest iteration of drug-eluting stent

Abbott’s Xience Skypoint stent. [Image from Abbott]

Abbott executive Dr. Nick West believes the company offers the “best-in-class” drug-eluting stent with its Xience platform.

When Abbott (NYSE:ABT) CMO & divisional VP of global medical affairs Dr. Nick West looks back at his use of drug-eluting stents in the early 2000s, all he sees now is innovation.

As a practicing interventional cardiologist, West remembers an earlier time in which the stents were barely deliverable. Each available platform had marked differences and each had its benefits and drawbacks.

“It’s fair to say that, if you look at the world of drug-eluting stents, they’ve evolved enormously,” West told Drug Delivery Business News. “They’ve just changed hugely.”

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Abbott launches trial for drug-eluting resorbable scaffold

Abbott (NYSE:ABT) announced today that it started the LIFE-BTK clinical trial for its Espirit BTK everolimus-eluting resorbable scaffold system.

According to a news release, Abbott’s Espirit system is the first to begin an investigational device exemption (IDE) trial in the U.S. for a fully resorbable device for treating below-the-knee blocked arteries or critical limb ischemia (CLI) in people battling advanced stages of peripheral artery disease (PAD).

Patients battling CLI currently undergo balloon angioplasty, the standard of care which Abbot said has shown poor short-term and long-term results and often the vessels become blocked again and require additional treatment. Presently, no drug-eluting stents, drug-coated balloons or bare-metal stents are approved for BTK use in the U.S.

Abbott’s Espirit BTK system is not a permanent implant, unlike traditional metal stents, and it offers support to an artery immediately after balloon angioplast…

Read more
  • 0